AstraZeneca ends R&D in India


Pharmaceutical firm AstraZeneca (AZ) is quitting its R&D site in Bangalore, India. The closure means 168 employees, researching neglected tropical diseases, tuberculosis (TB) and malaria, will lose their jobs as AZ drops its early-stage research into these areas.

The company will retain more advanced projects, such as AZD5847, which is in Phase II trials against TB. It will also outsource the site’s current product development functions, or transfer them to Macclesfield, UK. However, AZ confirmed it will maintain access to its compound library for open innovation projects in neglected diseases.

The closure is part of AZs ongoing restructuring programme, which began last year, will cost a total of 1600 jobs worldwide and see the company’s main UK R&D activities move from Alderley Park to Cambridge. After the closure, AZ will have just over 1000 staff in India, across manufacturing, sales and marketing roles.


Related Content

Succour for India's struggling scientists

21 January 2015 Managing Change

news image

The Right to Research foundation is helping Indian researchers to work their way into a job, as Rajesh Parishwad finds out

BASF to cut 350 jobs in plant science research

26 February 2016 Business

news image

Company will also close field trial sites in Hawaii, India and Puerto Rico

Most Commented

New law on legal highs approved in UK

1 February 2016 News and Analysis

news image

A blanket ban on New Psychoactive Substances has been given final approval and will come into force in April

WHO clarifies glyphosate risks

23 May 2016 Business

news image

UN and WHO panel conclude the herbicide glyphosate is ‘unlikely’ to cause cancer at realistic exposure levels